Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease

Clinical trial NCT00528242 · COMPLETED

Trial details

NCT number: NCT00528242
Sponsor: Response Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Raynaud's Disease

Start date: 2007-06-01
Primary completion: 2008-03-01
Enrollment: 17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.